SPONSOR
Lund University Hospital
Total Trials
2
Recruiting
2
Phases
Phase 3, Phase 2
Lund University Hospital is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Head and Neck Squamous Cell Carcinoma, Dedifferentiated Liposarcoma.
The trial portfolio spans Phase 3, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Lund University Hospital
How many clinical trials has Lund University Hospital sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Lund University Hospital, of which 2 are actively recruiting participants. These trials cover conditions including Head and Neck Squamous Cell Carcinoma, Dedifferentiated Liposarcoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Lund University Hospital research focus on?
Lund University Hospital clinical trials span Head and Neck Squamous Cell Carcinoma, Dedifferentiated Liposarcoma. The research pipeline includes Phase 3, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Lund University Hospital clinical trial?
To participate in a Lund University Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Lund University Hospital trials with current recruitment status updated daily.
Clinical Trials by Lund University Hospital
NCT06248996 Phase 3
Recruiting
a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients
Head and Neck Squamous Cell Carcinoma
NCT06389799 Phase 2
Recruiting
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
Dedifferentiated Liposarcoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology